FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to gastroenterology, and can be used to treat liver dysfunction. Methods of the invention relate to the administration of an effective amount of a methazolamide. Applications of the invention relate to the manufacture of a drug. Combinations of the invention relate to methazolamide and an antidiabetic agent. Compositions methazolamide and metformin in a ratio of 1:6.25–1:56.25.
EFFECT: use of inventions makes it possible to increase the effectiveness of treatment of fatty hepatosis and improve the liver function in the patient by reducing alanine aminotransferase (ALT) in the blood and lipid content in the liver.
49 cl, 3 dwg, 2 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF WEIGHT REDUCTION | 2013 |
|
RU2664442C2 |
| COMBINATION OF OMEGA-3 FATTY ACID AND SGLT-2 INHIBITOR FOR TREATING LIVER DISEASES | 2015 |
|
RU2695652C2 |
| COMBINED THERAPY WITH GPR119 AGONISTS AND DPP-4 INHIBITORS | 2020 |
|
RU2818562C2 |
| METHOD OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITH USING CYSTEAMINE PRODUCTS | 2008 |
|
RU2498795C2 |
| METHODS OF TREATING METABOLIC DISORDERS USING FGF21 VARIANTS | 2018 |
|
RU2815403C2 |
| COMPOSITION FOR IMPROVING OR PREVENTING NON-ALCOHOLIC FATTY LIVER DYSTROPHY | 2016 |
|
RU2746091C2 |
| COMPOUNDS FOR METABOLIC DISORDER TREATMENT | 2004 |
|
RU2349584C2 |
| COMPOSITIONS AND METHODS FOR TREATING DIABETES | 2004 |
|
RU2367423C2 |
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| FXR AGONISTS APPLICATION METHODS | 2017 |
|
RU2743075C2 |
